Impact of a Cardio-Oncology Unit on Prevention of Cardiovascular Events in Cancer Patients
Alessandra Cuomo(Federico II University Hospital), Carlo G. Tocchetti(Federico II University Hospital), Floriana Morgillo(University of Campania "Luigi Vanvitelli"), Francesca Wanda Rossi(Federico II University Hospital), Carmine De Angelis(Baylor College of Medicine), Michele Orditura(University of Campania "Luigi Vanvitelli"), Carminia Maria Della Corte(University of Campania "Luigi Vanvitelli"), Grazia Arpino(University of Naples Federico II), Maria Rosaria Galdiero(Humanitas University), Roberto Bianco(Federico II University Hospital), Teresa Troiani(University of Campania "Luigi Vanvitelli"), Stefania Napolitano(The University of Texas MD Anderson Cancer Center), Domenico Salvatore(CEINGE Biotecnologie Avanzate Franco Salvatore (Italy)), Marco Picardi(CEINGE Biotecnologie Avanzate Franco Salvatore (Italy)), Mario Giuliano(Regione Campania), Valentina Mercurio(Federico II University Hospital), Chiara Carlomagno(Federico II University Hospital), Antonio Carannante(Federico II University Hospital), Erika Martinelli(University of Campania "Luigi Vanvitelli"), Elide Matano(Regione Campania), Gilda Varricchi(Institute for Experimental Endocrinology and Oncology), Luigi Formisano(University of Naples Federico II), Ferdinando De Vita(University of Campania "Luigi Vanvitelli")
Cited by 22
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Macrophage plasticity and polarization in tissue repair and remodelling
|The Journal of Pathology|2012|2.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k